Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease

• Published in: Marine drugs Vol. 19; no. 4; p. 196
• Main Authors: Bilal, Muhammad, Nunes, Leonardo Vieira, Duarte, Marco Thúlio Saviatto, Ferreira, Luiz Fernando Romanholo, Soriano, Renato Nery, Iqbal, Hafiz M N
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 30.03.2021; MDPI
• Subjects: Algae; algal biome; Bioactive compounds; bioactive entities; Biological activity; Chemical compounds; Chemical synthesis; Defence mechanisms; Drug delivery systems; Drug therapy; engineered cues; Exploitation; Hydrogels; Immune response; Immune system; Immunity; Immunosuppressive agents; Inflammation; Inflammatory bowel disease; Inflammatory bowel diseases; Intestine; Irritable bowel syndrome; Marine biology; Marine environment; Molecular modelling; Nanoparticles; Performance evaluation; Pharmacokinetics; polysaccharides; Resources; Review; Robustness; Specificity; Structure-function relationships; Surgery; therapeutic attributes; Translation; Tumor necrosis factor-TNF; China; polysaccharides; engineered cues; therapeutic attributes; bioactive entities; inflammatory bowel disease; algal biome
• ISSN: 1660-3397; 1660-3397
• DOI: 10.3390/MD19040196

Naturally occurring biological entities with extractable and tunable structural and functional characteristics, along with therapeutic attributes, are of supreme interest for strengthening the twenty-first-century biomedical settings. Irrespective of ongoing technological and clinical advancement, traditional medicinal practices to address and manage inflammatory bowel disease (IBD) are inefficient and the effect of the administered therapeutic cues is limited. The reasonable immune response or invasion should also be circumvented for successful clinical translation of engineered cues as highly efficient and robust bioactive entities. In this context, research is underway worldwide, and researchers have redirected or regained their interests in valorizing the naturally occurring biological entities/resources, for example, algal biome so-called "treasure of untouched or underexploited sources". Algal biome from the marine environment is an immense source of excellence that has also been demonstrated as a source of bioactive compounds with unique chemical, structural, and functional features. Moreover, the molecular modeling and synthesis of new drugs based on marine-derived therapeutic and biological cues can show greater efficacy and specificity for the therapeutics. Herein, an effort has been made to cover the existing literature gap on the exploitation of naturally occurring biological entities/resources to address and efficiently manage IBD. Following a brief background study, a focus was given to design characteristics, performance evaluation of engineered cues, and point-of-care IBD therapeutics of diverse bioactive compounds from the algal biome. Noteworthy potentialities of marine-derived biologically active compounds have also been spotlighted to underlying the impact role of bio-active elements with the related pathways. The current review is also focused on the applied standpoint and clinical translation of marine-derived bioactive compounds. Furthermore, a detailed overview of clinical applications and future perspectives are also given in this review.